An investigation on behalf of investors of Shire plc (NASDAQ: SHPG) in connection with the proposed takeover was announced.
San Diego, CA -- (SBWIRE) -- 05/16/2018 -- An investigation was announced for investors, who currently hold shares of Shire plc (NASDAQ: SHPG), over the takeover of Shire plc. by Takeda Pharmaceutical Company.
Investors who purchased shares of Shire plc (NASDAQ: SHPG) and currently hold any of those NASDAQ: SHPG shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Shire plc breached their fiduciary duties owed to NASDAQ: SHPG investors in connection with the proposed acquisition.
On May 8, 2018, Shire plc (NASDAQ: SHPG) and Takeda Pharmaceutical Company Limited ("Takeda") announced that they reached agreement on the terms of a recommended offer pursuant to which Takeda Pharmaceutical Company Limited will acquire the entire issued and to be issued ordinary share capital of Shire plc. Under the terms of the transaction, Shire shareholders will receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire they own.
However, the investigation concerns whether the offer is unfair to Shire plc (NASDAQ: SHPG stockholders. More specifically, the investigation concerns whether the Shire plc (NASDAQ: SHPG Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Shire plc (NASDAQ: SHPG) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego